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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
aztreonam lysine for inhalation is effective in the treatment of patients with cystic fibrosis and
Pseudomonas aeruginosa airway infection.
STUDY DESIGN: Review of three English language primary randomized controlled trials
published in 2008, 2009, and 2011.
DATA SOURCES: Three randomized, double-blind, placebo-controlled studies using Cochrane
and Pubmed databases.
OUCOMES MEASURED: Patient oriented outcomes measured included change in respiratory
symptoms measured by the Cystic Fibrosis Questionnaire-Revised and need for additional
antipseudomonal antibiotics indicative of pulmonary exacerbation.
RESULTS: In both cystic fibrosis (CF) patients who have been treated with standard long term
therapy and those who have not, 28 day therapy with aztreonam lysine for inhalation (AZLI) was
shown to be effective in the treatment of chronic Pseudomonas aeruginosa airway infection.
AZLI treatment showed statistical significance in the improvement of patient reported
respiratory symptoms compared to placebo. Twice per day versus three times per day dosing did
not show a significant impact on outcome. In CF patients with mild respiratory dysfunction,
determined by a FEV1 of > 75%, AZLI treatment did not significantly prevent need for
additional antipseudomonal antibiotics during the course of the study.
CONCLUSION: These studies determined that AZLI is more effective at reducing respiratory
symptoms in CF patients with chronic P. aeruginosa airway infection than placebo. AZLI
therapy does not significantly decrease the number of severe pulmonary exacerbations that
would require further antipseudomonal antibiotics. Twice or three times per day dosing does not
significantly affect the outcomes.
KEY WORDS: aztreonam, monobactam, cystic fibrosis, Pseudomonas aeruginosa
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INTRODUCTION
Cystic fibrosis (CF) is a chronic, autosomal recessive disease of the secretory glands.1,2 It
is characterized by increased pulmonary secretions which are especially thick and difficult to
clear.1 Common complications include superimposed airway infections and pancreatic
insufficiency due to mucus blocked ducts.1 The most common pathogen of airway infections in
CF patients, and one of the most difficult to eradicate, is Pseudomonas aeruginosa (P.
aeruginosa).1 Chronic airway infections are associated with a progressive decrease in lung
function and overall increased patient morbidity and mortality.1
Due to the recessive pattern of inheritance for CF, an affected individual must acquire
one abnormal gene from each parent. Approximately 30,000 people in the United States are
affected by CF, however, over 10 million Americans are carriers of the abnormal cystic fibrosis
transmembrane conductance regulator (CFTR) gene.2, 3 This condition affects all races,
ethnicities and genders, but is most commonly found among Northern Europeans.2 The precise
cost of treating CF in recent years is unknown, however data from 1996 shows the direct cost per
patient per year was up to $16,300 and lifetime direct costs were between $200,000 and
$300,000.4 The exact number of healthcare visits per year for CF patients has not been explicitly
calculated, however the recommendation is for quarterly evaluations, not including visits or
hospitalizations for worsening symptoms or pulmonary exacerbations, medication changes,
social work visits or dietary evaluations.5
CF is caused by an inherited defect in the CFTR gene that encodes for an ion channel
protein responsible for controlling salt and water movement within the cell.2 There are a wide
variety of known mutations that can affect the function of the CFTR gene, however all create a
dysfunctional protein which results in thick, persistent mucus secretions.2 Symptoms involve the
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sinuses, lungs, skin, liver, pancreas, gastrointestinal tract and reproductive organs and include
salty sweat, increased thick mucus production leading to chronic sinus and airway infections,
dyspnea, pancreatitis, diabetes, malnutrition, and infertility.2 Respiratory failure is the most
common cause of death in CF patients, and it is due to an accumulation of tissue damage from
chronic and/or recurrent pulmonary infections.2 There is no known cure for CF at this time.3
Treatment of CF is multifactorial and involves a variety of body systems and treatment
methods. Patients are instructed in a variety of airway clearance techniques including postural
drainage, percussion, inflatable vests, pulmonary rehabilitation with exercise training, and
breathing strategies.3,6 Inhaled medications such as mucolytics, antibiotics, bronchodilators and
hypertonic saline, as well as oral or IV antibiotics in severe exacerbations, have been utilized for
airway infections and worsening respiratory symptomatology.3,6 Nutrition is another focus, with
supplementation implemented involving a high caloric diet, feeding tube, pancreatic enzyme
supplementation and specific nutrient supplementation when medically necessary.3,6 Surgical
procedures including nasal polyp removal, endoscopy with lavage, and lung transplantation are
employed as a last resort to aid in respiratory function.3,6
Currently, tobramycin is the most commonly used inhaled antibiotic for exacerbations of
respiratory infections in CF patients, and has been shown to be effective against P. aeruginosa.3,6
Since aztreonam is a monobactam antibiotic that has also been shown to have antipseudomonal
properties, many studies have begun to explore inhaled aztreonam lysine as a potential effective
intervention to relieve symptoms and treat P. aeruginosa airway infection.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not aztreonam
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lysine for inhalation is effective in the treatment of patients with cystic fibrosis and
Pseudomonas aeruginosa airway infection.
METHODS
Three randomized, double-blind, placebo-controlled studies were included in this
selective EBM review. The studies involved males and females 6 years of age and older with
established CF and P. aeruginosa airway infection. Inclusion criteria consisted of studies that
were randomized, controlled, double blind and published after 1996, with patients that were 6
years of age and older with current P. aeruginosa airway infections. Exclusion criteria comprised
of patients under the age of 6 and those that utilized repeated courses of treatment with AZLI.
The intervention was inhaled aztreonam lysine (AZLI) via nebulizer with a formulation
of 75 mg of aztreonam and 52.5 mg of lysine monohydratae diluted in 1 mL of 0.17% NaCl. The
comparison group received a visually matched placebo via nebulizer with a formulation of 5 mg
lactose diluted in 1mL of 0.17% NaCl. Outcomes addressed included patient-reported impact on
respiratory symptoms and symptom or health exacerbation requiring use of oral, IV or additional
inhaled antipseudomonal antibiotics. Outcomes were measured by utilizing the CF
Questionnaire-Revised where points ranged from 0-100 and increasing scores indicated
improvement of symptoms, as well as explicitly counting patients who required use of added
antipseudomonal antibiotics during the treatment or follow up period specified by the individual
study.
Author searched articles within PubMed and The Cochrane Central Register of
Controlled Trials (CENTRAL) databases between 2012 and 2013. Searches were conducted
using keywords “aztreonam,” “monobactam,” “cystic fibrosis,” and “Pseudomonas aeruginosa.”
Included articles were published in English, in 2008, 2009 and 2011, and selected based on their
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relevance to CF patients with P. aeruginosa airway infections and because they addressed
patient-oriented outcomes (POEMs). Each article was published in a peer-reviewed journal.
Table 1 – Demographics and Characteristics of Included Studies
Study Type # Pts
McCoy Double 246
(2008)1 -blind
RCT

Age
≥6
yrs
old

Retsch- Double 164 ≥ 6
Bogart -blind
yrs
7
(2009) RCT
old

Wain- Double 160 ≥ 6
wright -blind
yrs
(2011)8 RCT
old

Inclusion Criteria
≥ 6 yrs old,
documented CF,
current P.
aeruginosa
airway infection,
3+ tobramycin
inhalation
solution courses
w/i last yr

Exclusion Criteria
W/D
- Current oral corticosteroid use, daily 156
O2 supplementation or intolerance to
the study’s medications
- Recent changes in antimicrobial,
bronchodilator, anti-inflammatory,
corticosteroid medications or
physiotherapy technique/schedule
- Acute findings on chest radiograph w/i
past 90 days, high AST, ALT, or SCr
levels, or airway cultures of
FEV1 ≥ 25% and Burkholderia cepacia w/i past 2 yrs
≤ 75% predicted, - Pregnant, lactating, lung transplant, or
arterial oxygen a medical or psychiatric illness
saturation ≥ 90% interfering with study
on room air
≥ 6 yrs old,
- Anti-pseudomonal antibiotic or
40
documented CF, azithromycin use w/i past 28 days
- Current oral corticosteroid use, daily
P. aeruginosa
airway infection, O2 supplementation >2 L/min at night
FEV1 ≥ 25% to ≤ or intolerance to the study’s
75% predicted, medications
arterial oxygen - Recent changes to antimicrobial,
saturation ≥ 90% bronchodilator, anti-inflammatory or
on room air
corticosteroid medications or
physiotherapy technique/schedule
- Acute findings on chest radiograph w/i
90 days, high AST, ALT, or SCr levels,
or airway cultures of Burkholderia
cepacia w/i past 2 yrs
- Pregnant, lactating, lung transplant, or
a medical or psychiatric illness that
interferes with study
≥ 6 yrs,
- Pregnant, lactating, lung transplant, or 4
documented CF, a medical or psychiatric illness that
interferes with study participation
P. aeruginosa
airway infection, - Previous enrollment in AZLI trial, or
FEV1 ≥ 75%
acute findings on chest radiograph
predicted;
- Changes in antimicrobial,
≥ 2 chronic or
bronchodilator, or corticosteroid
intermittent CF medications or physiotherapy
symptoms for ≥ technique/schedule w/i 7 days
28 days before -Anti-pseudomonal antibiotic w/i past
baseline
28 days
-Intolerance to the study’s medications

Intervention
28 day
course of
tobramycin
inhalation
solution
(TIS)
followed by
a 28 day
course of 75
mg AZLI
with
nebulizer
BID or TID

28 day
treatment
course of 75
mg
aztreonam
lysine for
inhalation
administere
d by
nebulizer
TID

28 day
course of
AZLI with
nebulizer
TID (doses
separated ≥
4 hrs)
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The statistics utilized from the article or calculated by the author included relative benefit
increase (RBI), absolute benefit increase (ABI), number needed to treat (NNT), relative risk
increase (RRI), absolute risk increase (ARI), number needed to harm (NNH), 95% confidence
intervals (CI) and p-values.
OUTCOMES MEASURED
There were a variety of outcomes addressed by each study, however the author utilized
outcomes that served as POEM’s to address the research question.
McCoy et al (2008) included patients with significant lung disease (FEV1 ≥ 25% to ≤
75% predicted) and who had been compliant with the standard CF treatment of maintenance
tobramycin inhalation solution (TIS) treatment courses in their study. All study participants were
administered a 28 day course of open-label TIS (300 mg twice daily) and then randomized into a
1:1:1 grouping of AZLI (75mg of aztreonam, 52.5 mg of lysine monohydrate diluted in 1 mL of
0.17% NaCl solution) either twice or three times daily, or placebo (5 mg lactose diluted in 1 mL
of 0.17% NaCl solution) via nebulizer for a treatment period of 28 days. Patients were monitored
on Day 14, Day 28, and Days 42, 56, 70 and 84 during the follow up period. The outcome
addressed was change in patient reported respiratory symptoms, measured by utilizing the Cystic
Fibrosis Questionnaire-Revised (CFQ-R). Minimal clinically important difference (MCID) score
of 5 was used by to analyze results as it corresponds to the smallest change in symptoms
noticeable by patients. Therefore, a 5 point change or more indicated improved or worsened
symptoms. At Day 28 of treatment, patients were categorized as improved ( ≥ 5 point increase
from baseline CFQ-R Respiratory scores), worsened ( ≥ 5 point decrease from baseline)
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or stable/unchanged (< 5 point change). Comparisons between the experimental and the control
groups were made throughout treatment and the designated follow up period.
Retsch-Bogart et al (2009) focused on patients with moderate to severe lung disease
(determined by a FEV1 ≥ 25% to ≤ 75% predicted) who had not been administered any inhaled,
IV, or oral anti-pseudomonas antibiotics, azithromycin or aerosolized hypertonic saline solution
within the past 28 days prior to the date of screening. Patients were split into groups via a 1:1
randomization, with the interventional group receiving 75 mg AZLI administered by nebulizer
three times daily for 28 days and the control group receiving a visually matched placebo at the
same interval for the same duration of time. The outcome addressed was change in patient
reported respiratory symptoms, measured by the CFQ-R. Analysis of the questionnaire and
MCID were the same as McCoy et al. Patients were followed throughout treatment and the 2
week follow up period. Comparisons between the experimental and control groups were made.
Wainwright et al (2011) selected for patients with mild lung disease (FEV1 ≥ 75%
predicted). Patients were randomly assigned (1:1) to treatment with 75 mg AZLI or placebo by
nebulizer three times per day, doses separated by more than 4 hrs, for 28 days. Patients were
monitored at Day 14, 28, and 42 for follow-up. The outcome was symptom(s) or health
exacerbation requiring use of oral, IV, or additional inhaled antipseudomonal antibiotics during
the study (28 day treatment period and 14 day follow up). The outcome was measured by
explicitly counting the number of patients who required use of additional antipseudomonal
antibiotics in the control and experimental groups.
RESULTS
The focus of this EBM review is patient oriented outcome measures, so only those will be
presented in the following section. Two of the randomized control trials, McCoy et al and
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Retsch-Bogart et al, utilized the CFQ-R to determine patient reported respiratory symptoms as a
means to evaluate the treatments. The third study assessed pulmonary exacerbation that required
additional antipseudomonal antibiotics to determine patient outcome.
In McCoy et al, of the 246 patients enrolled and assigned groups by a 1:1:1
randomization, 211 completed the 28 day course of TIS and received at least 1 dose of AZLI or
placebo, and therefore comprised the intention to treat population.1 173 patients (82%)
completed the 28 day treatment, and 90 (43%) completed the follow-up period.1
Responses of twice versus three times per day dosing placebo groups were pooled for the
efficacy analyses and were compared with the AZLI-pooled group. Analysis of CFQ-R used the
last observation carried forward convention. At the conclusion of treatment (Day 28), adjusted
mean CFQ-R respiratory scores increased 5.01 points in the AZLI-pooled group compared to
placebo (95% CI, 0.81 to 9.21; P = 0.020), showing significance for AZLI in decreasing
respiratory symptoms versus placebo.1 During the treatment period, the AZLI-treated patients
had more improved CFQ-R respiratory scores and less worsened respiratory scores compared
with placebo-treated patients (overall categorical comparison, P = 0.029).1 52% of AZLI treated
patients and 37% of placebo had a greater than 5 point increase in respiratory score and 28% of
AZLI versus 38% of placebo had a greater than 5 point decrease in respiratory score.1 For
improved CFQ-R scores, the RBI was calculated to be 40.54%, the ABI was 15% and the NNT
was seven (Table 2). Therefore, for every 7 patients treated with AZLI, one more patient showed
improved respiratory symptoms compared to the control. For worsened CFQ-R scores, the
calculated RRI was -26.32%, the ARI was -10% and the NNH was -10 patients (Table 3). This
means that for every 10 patients treated with AZLI, one less had worsened respiratory symptoms.
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Table 2. Improved Respiratory Score on CRQ-R During Treatment Period (Day 0-28)1
CER
EER
RBI
ABI
NNT
37%
52%
41%
15%
7 patients
Table 3. Worsened Respiratory Score on CRQ-R During Treatment Period (Day 0-28)1
CER
EER
RRI
ARI
NNH
38%
28%
-26%
-10%
-10 patients

The study of Retsch-Bogart, et al focused on patients without recent use of
antipseudomonal antibiotics or azithromycin and had a primary efficacy endpoint of change in
patient reported respiratory symptoms analyzed through the use of the CFQ-R scale. Patients
were randomly assigned (1:1) a 28 day treatment of 75 mg AZLI or placebo at three times per
day dosing and monitored throughout treatment and a 14 day follow up period.7 Of the 164
patients who enrolled and began treatment, 138 completed the 28 day treatment period and 124
(76%) completed the study through the follow-up.7 At day 28, patients were categorized as
improved, worse, or stable based on their change from baseline CFQ-R respiratory scores. Five
point or greater changes were determined to be the minimal clinically important difference and
used to dichotomize the patient data into the categories by Retsch-Bogart, et al.7
The adjusted mean CFQ-R respiratory scores showed a significant improvement in the
AZLI group and decline in the placebo group at Day 28, the conclusion of the treatment period
(9.7 point difference, 95% CI, 4.3 to 15.1; P < 0.001).7 Also established at the conclusion of
treatment, the data showed AZLI was shown to be significantly better in improving CFQ-R
respiratory scores, and less likely to cause worsened respiratory scores, compared to the placebo
group (P = 0.006 for overall comparison).7 In the AZLI group, 56% showed a greater than 5
point increase in respiratory score and 25% showed a greater than 5 point decrease in respiratory
score, compared with the placebo group of 37% and 45%, respectively.7 The calculated NNT
was 6, meaning that for every 6 patients treated with AZLI, one more had improved respiratory
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symptoms (Table 4). The calculated NNH was -5, meaning that for every 5 patients treated with
AZLI, one less patient will have worsened respiratory symptoms (Table 5).
Table 4. Improved Respiratory Score on CRQ-R at Treatment End (Day 28)7
CER
EER
RBI
ABI
37%
56%
51%
19%

NNT
6 patients

Table 5. Worsened Respiratory Score on CRQ-R at Treatment End (Day 28)7
CER
EER
RRI
ARI
NNH
45%
25%
-44%
-20%
-5 patients
In Wainwright, et al, patients were treated with 28 days of 75 mg AZLI or placebo at
three times per day dosing and followed for an additional 14 days.8 The study enrolled and
randomly assigned 160 patients, 156 (98%) of which completed the study.8 Efficacy was
assessed by comparing the number of patients that required additional oral, IV, or inhaled
antibiotics during the treatment period and follow up. The need for additional antibiotics was
similar amongst both the experimental and control groups from baseline through the follow up
period (AZLI, 25%; placebo, 25.9%; p >0.999).8 AZLI treatment did not significantly prevent
symptoms or health exacerbations requiring additional antibiotics. The calculated NNH was 112. This means that for every 112 patients treated with AZLI, one less will require additional
antipseudomonal antibiotics than compared to the control (Table 6)
Table 6. Need for Additional Antipseudomonal Antibiotics During Study8
CER
EER
RRI
ARI
25.9%
25%
3.5%
0.9%

NNH
-112 patients

DISCUSSION
To summarize the data within the three studies analyzed, it can be concluded that 75 mg
of AZLI is effective at reducing respiratory symptoms in CF patients with chronic P. aeruginosa
airway infection and moderate to severe respiratory dysfunction (FEV1 between 25% and 75%
predicted) compared to placebo. AZLI therapy did not significantly decrease the severe
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pulmonary exacerbations that would require further antipseudomonal antibiotics in patients with
mild respiratory dysfunction, or a FEV1 > 75% predicted. However, in the study that evaluated
need for additional antibiotics, patients had a modest symptomatic baseline, and therefore any
deviation from that may have prompted patients to seek additional treatment whether they truly
needed it or not.
There were several limitations and flaws in the three research studies. While this EBM
review included a population of CF patients over the age of 6, all three of these studies had
significantly more adults participate than children. The study performed by McCoy, et al
specifically had 78% of their participants over the age of 18.1 Retsch-Bogart, et al utilized a
population where 77.4% were over the age of 18. As a general rule, along with standards of care
at this point in time, more adults than children will have the moderate to severe lung impairment
necessary to enter this specific study, and their disease progression may be more responsive to
treatment. Therefore, these two studies may conclude a greater efficacy for children <18 years
old than might be accurate. Also with Retsch-Bogart, et al, the participants were treated with TIS
before AZLI or placebo. This makes it difficult to state clearly whether AZLI alone showed
significant benefit to patients, or if it was the adjunctive treatment with TIS that provided
significant symptom improvement.
Two of the three studies in this EBM review shared a significant patient drop out rate.
While there were a wide variety of reasons as to the cause, poor patient compliance is a large
issue both in research and in the medical field. In the United States, as of 2005, of the long term
treatments currently available, specifically TIS or macrolide therapy, 46% of eligible CF patients
over the age of 6 were not receiving maintenance treatment.7 In addition, patient compliance
rates were less than ideal, ranging from 51% in older patients to 73% in younger individuals.7
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Researchers and medical professionals need to work together with patients to develop additional
treatment options for patients with chronic P. aeruginosa airway infection and emphasize the
importance of treatment compliance for reducing morbidity and mortality.
CONCLUSION
According to the data generated from the three research studies compiled in this systemic
review, AZLI has shown to be an effective treatment for patients with CF and chronic P.
aeruginosa airway infection, whether pretreated with TIS and received proper maintenance
therapy or not.
Future research studies need to address whether inhaled antibiotic monotherapy is more
efficacious in preventing pulmonary exacerbations and treating P. aeruginosa airway infections
or if multiple products would provide greater benefit to patients. A longitudinal study to assess
patient health both pre- and post-treatment periods with inhaled antibiotics, and to determine if
multiple treatments would be more or less valuable to CF patients with chronic P. aeruginosa
airway infection would be a useful undertaking. AZLI evaluated in the short term in these three
studies has shown to be effective, but further investigation is necessary to determine if its’ use as
a long-term suppressive therapy would be beneficial.
Cystic fibrosis is a challenging condition to treat. Pulmonary involvement is debilitating
for patients with regards to their ability to carry out daily activities. P. aeruginosa is notorious
for being difficult to eradicate and responsible for increased mortality of those infected.1
However, medical professionals have limited antibiotics that have shown to be both safe and
effective in P. aeruginosa treatment. With continued research and patient compliance, CF
patients will have improved quality of life and clinical outcomes.
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